Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arch Therapeutics Inc (ARTH)

Arch Therapeutics Inc (ARTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,498
  • Shares Outstanding, K 3,094
  • Annual Sales, $ 80 K
  • Annual Income, $ -6,980 K
  • 60-Month Beta 3.57
  • Price/Sales 74.37
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ARTH with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.78
  • Most Recent Earnings $-0.57 on 02/20/24
  • Latest Earnings Date 01/05/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.21
  • Growth Rate Est. (year over year) +475,614.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7600 +19.32%
on 02/22/24
3.4000 -38.24%
on 02/15/24
-0.9000 (-30.00%)
since 02/14/24
3-Month
1.7600 +19.32%
on 02/22/24
9.0000 -76.67%
on 12/26/23
-2.5300 (-54.64%)
since 12/14/23
52-Week
0.3900 +438.46%
on 10/11/23
18.0000 -88.33%
on 12/05/23
-1.7000 (-44.74%)
since 03/14/23

Most Recent Stories

More News
Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing

Uplisting is the Next Significant Step...

ARTH : 2.1000 (+15.38%)
Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel

Initial A4100 code being deployed and application for specific HCPCS product code to be submitted in the second calendar quarter...

ARTH : 2.1000 (+15.38%)
Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring

World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on Success with AC5® Advanced Wound System...

ARTH : 2.1000 (+15.38%)
Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring

Additional data covered a variety of specialties, including vascular surgery, plastic surgery, general surgery, and podiatry, to further support clinical...

ARTH : 2.1000 (+15.38%)
Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring

Additional case studies and key opinion leader discussion continues to support the broad potential of AC5® Advanced Wound System...

ARTH : 2.1000 (+15.38%)
Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System

Strategic Alliance Positioned to Grow Sales Opportunities in Non-Government Hospital Channel...

ARTH : 2.1000 (+15.38%)
Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities

AC5® Advanced Wound System demonstrated notable improvement in healing after only 3 to 6 applications—with only weekly clinic visits and reapplication...

ARTH : 2.1000 (+15.38%)
Arch Therapeutics Announces Appointment of Guy Fish to the Board

Brings Broad Industry Experience in Strategy and Execution...

ARTH : 2.1000 (+15.38%)
Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System

Significantly Expands Access to Include All Federal Government Agencies...

ARTH : 2.1000 (+15.38%)
Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program

Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5® Advanced Wound System FRAMINGHAM, Mass., Dec. 01, 2021 ...

ARTH : 2.1000 (+15.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 2.3667
2nd Resistance Point 2.2333
1st Resistance Point 2.1667
Last Price 2.1000
1st Support Level 1.9667
2nd Support Level 1.8333
3rd Support Level 1.7667

See More

52-Week High 18.0000
Fibonacci 61.8% 11.2730
Fibonacci 50% 9.1950
Fibonacci 38.2% 7.1170
Last Price 2.1000
52-Week Low 0.3900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar